The open-label study results demonstrated that Lantus and Apidra helped in lowering blood glucose levels in the study as compared to premixed insulin with less hypoglycemia and also improves diabetes-specific quality of life.
The study results supported the non-inferiority of Lantus plus up to 1 injection of Apidra versus two-injections of premixed insulin, while in the Lantus plus up to 3 injections of Apidra arm, superiority versus premixed insulin was not shown.
Oregon Health and Science University Section of Diabetes head Matthew Riddle said optimization of insulin dosage with glargine plus a single mealtime injection of glulisine allowed more patients to reach target A1C levels than with twice-daily premixed insulin, and with less hypoglycemia.
"These findings support a stepwise approach to addition of mealtime insulin when basal insulin with oral agents is not sufficient to maintain control," Riddle said.